TB-500 Dosing and Reconstitution: A 2026 UK Research Reference to Doses, Protocol Design, Storage and Route Selection

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. Dosing framing for TB-500 research
• 2. Published dose ranges
• 3. Reconstitution protocol
• 4. Injection routes
• 5. Frequency — weekly vs twice-weekly
• 6. Duration by study type
• 7. Storage and aliquoting
• 8. Dose selection by research model
• 9. Comparison to BPC-157 protocols
• 10. Combination protocols
• 11. UK procurement and quality
• 12. Frequently asked questions
• 13. References

1. Dosing framing for TB-500 research

TB-500 (synthetic active-region analogue of thymosin beta-4) is an investigational peptide for UK laboratory research only. This guide summarises the published rodent protocol conventions to support UK research scientists designing in vitro, ex vivo, or licensed animal studies.

2. Published dose ranges

TB-500 rodent doses in the published literature commonly include:

• 150 µg/kg: used in some mouse studies, particularly cardiac research
• 2 mg per animal (absolute dose): typical low-end of absolute-dose protocols
• 5 mg per animal: common mid-range
• 10 mg per animal: common upper-range

Note the convention difference: some published protocols use per-kg dosing (typical in rigorous pharmacological studies), others use absolute per-animal dosing (common in tissue-repair protocols). Scientists should verify which convention applies to any specific protocol reference.

3. Reconstitution protocol

TB-500 is supplied lyophilised. Reconstitution with bacteriostatic water for injection (preserved with 0.9% benzyl alcohol) is standard — this supports multi-week storage at 2-8°C.

Reconstitution math for a 5 mg vial:

• 1 ml diluent → 5 mg/ml (high concentration)
• 2 ml diluent → 2.5 mg/ml (common research reference)
• 5 ml diluent → 1 mg/ml (for small-volume aliquots)

Reconstitution procedure:

1. Swab vial rubber seal with alcohol wipe.
2. Inject bacteriostatic water slowly down the inner wall of the vial.
3. Swirl gently (do not shake) until fully dissolved.
4. Inspect clarity — should be clear with no particulates.

4. Injection routes

Route of administration in published TB-500 rodent research:

• IM (intramuscular): most common; sustained release profile
• SC (subcutaneous): widely used; slower absorption
• IP (intraperitoneal): systemic rapid delivery
• IV (intravenous): in some cardiac acute studies
• Intracardiac / local: in specific cardiac research protocols

Unlike BPC-157, TB-500 does not have strong oral-activity evidence — injection routes are the standard.

5. Frequency — weekly vs twice-weekly

TB-500 is commonly dosed less frequently than BPC-157:

• Weekly — most common in tissue-repair protocols
• Twice-weekly — used in more acute research models or when higher sustained exposure is the design goal
• Daily — less common; when used, typically at lower per-dose amounts

The less-frequent dosing reflects TB-500’s apparently longer half-life relative to BPC-157. However, rigorous comparative PK data between the two peptides are limited.

6. Duration by study type

Typical protocol durations:

• Acute injury (muscle, tendon, cardiac): 2-4 weeks
• Subacute recovery studies: 4-6 weeks
• Chronic remodelling or long-term studies: 6-12 weeks
• Research safety studies: 12+ weeks in extended protocols

7. Storage and aliquoting

Storage reference:

• Lyophilised TB-500 (unopened): 2-8°C for 2 years; −20°C for extended-storage.
• Reconstituted in bacteriostatic water: 2-8°C protected from light; approximately 28 days stable (verify against COA).
• Reconstituted in sterile water: use same day; otherwise aliquot and freeze at −20°C.
• Aliquoted for freezer: single-use microtube aliquots at −20°C (−80°C preferred for long-term).

Pragmatic workflow for a 5 mg vial supporting a 4-week study:

1. Reconstitute in 2 ml bacteriostatic water → 2.5 mg/ml.
2. Store at 2-8°C, protected from light.
3. Draw weekly doses sterilely.
4. Discard remaining peptide after 28 days or if any sign of degradation.

8. Dose selection by research model

Representative doses by endpoint:

• Cardiac post-MI (mouse): 150 µg/kg IP, often single or repeated dosing in acute protocols
• Cardiac post-MI (rat): higher absolute doses, scaled by species weight
• Skeletal muscle injury (rat): 2-10 mg per animal, IM or SC, weekly for 2-6 weeks
• Dermal wound healing: topical or systemic dosing depending on design
• Corneal wound healing: topical administration in eye drops (specialised formulation)
• CNS / stroke models: typically IP or SC systemic administration

9. Comparison to BPC-157 protocols

Side-by-side:

• BPC-157: 10 µg/kg daily, IP or IM, for 14-30 days
• TB-500: 2-10 mg per animal weekly or twice-weekly, IM or SC, for 2-6 weeks

Both peptides reconstitute in bacteriostatic water and use similar storage protocols. The main differences are dose-per-administration amount, dosing frequency, and route emphasis (BPC-157 supports oral activity; TB-500 does not strongly).

10. Combination protocols

Some research protocols combine TB-500 and BPC-157, reasoning that the complementary mechanisms (actin cytoskeleton regulation + VEGFR2/FAK angiogenesis and fibroblast migration) should compound. Evidence for synergistic effect in rigorous factorial designs is limited. Combination protocols typically use each peptide at its standard dose and frequency, maintained across the combination arm.

See our BPC-157 vs TB-500 Comparison for the mechanism and protocol contrast.

11. UK procurement and quality

UK research-grade TB-500 procurement requirements:

• ≥ 98% HPLC (≥ 99% emerging 2026 standard)
• Sequence explicitly disclosed on COA (supplier-to-supplier variation)
• Identity MS confirmation per batch
• Batch-specific Certificate of Analysis
• Lyophilised format, UK cold-chain dispatch
• Endotoxin testing for cell/animal work batches

See our Research-Grade Peptides Guide for standards detail and UK Research Peptide Buying Guide for sourcing due diligence.

12. Frequently asked questions

What is the typical TB-500 dose in rodent studies?

Typical doses span 2-10 mg per animal absolute (varying by study convention), with weekly or twice-weekly administration over 2-6 weeks. Cardiac studies often use per-kg dosing (e.g., 150 µg/kg).

How should TB-500 be reconstituted?

Add bacteriostatic water to the vial slowly down the inner wall, swirl gently. A 5 mg vial in 2 ml bacteriostatic water produces 2.5 mg/ml — the common research concentration.

How long is reconstituted TB-500 stable?

Approximately 28 days at 2-8°C in bacteriostatic water, protected from light. Verify against the batch-specific COA.

Weekly or twice-weekly dosing — which is better?

Most published tissue-repair protocols use weekly administration. Twice-weekly is an option for more acute models or when higher sustained exposure is the design goal. The choice should be protocol-specific.

Is TB-500 effective orally?

Unlike BPC-157, TB-500 does not have strong evidence for retained oral activity. Injection routes are the standard research convention.

What’s the difference in dosing frequency between TB-500 and BPC-157?

BPC-157 is typically dosed daily despite its short half-life (PK-PD disconnect). TB-500 is typically dosed weekly or twice-weekly, reflecting a longer apparent biological half-life.

Can TB-500 be combined with BPC-157?

Combination protocols exist but rigorous evidence for synergistic vs additive effect is limited. Factorial-design protocols (vehicle / TB-500 / BPC-157 / combination) are needed to resolve the question.

13. References

1. Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin β4: a multi-functional regenerative peptide. Expert Opin Biol Ther 2012;12(1):37-51.
2. Bock-Marquette I, Saxena A, White MD, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature 2004;432(7016):466-472.
3. Smart N, Risebro CA, Melville AA, et al. Thymosin β4 induces adult epicardial progenitor mobilization and neovascularization. Nature 2007;445(7124):177-182.
4. Sosne G, Qiu P, Goldstein AL, Wheater M. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. FASEB J 2010;24(7):2144-2151.
5. Malinda KM, Sidhu GS, Mani H, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol 1999;113(3):364-368.
6. Philp D, Goldstein AL, Kleinman HK. Thymosin beta 4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev 2004;125(2):113-115.
7. Sosne G, Szliter EA, Barrett R, et al. Thymosin beta 4 promotes corneal wound healing. Exp Eye Res 2002;74(2):293-299.
8. Crockford D, Turjman N, Allan C, Angel J. Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications. Ann N Y Acad Sci 2010;1194:179-189.
9. Morris DC, Chopp M, Zhang L, Zhang ZG. Thymosin beta4: a candidate for treatment of stroke? Ann N Y Acad Sci 2010;1194:112-117.
10. Bollini S, Riley PR, Smart N. Thymosin β4: multiple functions in protection, repair and regeneration of the mammalian heart. Expert Opin Biol Ther 2015;15 Suppl 1:S163-174.

UK Research Cluster Hubs

• TB-500 UK Research Guide
• BPC-157 UK Research Guide
• GLP-1 Peptides Complete Research Reference
• Retatrutide UK Research Guide
• Tirzepatide UK Research Guide
• Research-Grade Peptides Standards Guide
• UK Research Peptide Buying Guide

Disclaimer: TB-500 is an investigational peptide not approved for human use in the UK, EU or US. All products supplied by Peptides Lab UK are for licensed in vitro and ex vivo laboratory research purposes only. Not for human consumption, veterinary use, or any therapeutic application.